Abraxane Lung Cancer Approval Comes With Questionable Commercial Value
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears Celgene’s Abraxane in lung cancer despite its lack of even a progression-free survival benefit. But the ease of approval is reassurance ahead of the release of melanoma results, with a PFS benefit, in November.